Agios Pharmaceuticals | AGIO - Selling And Administration Expenses

Stock Price
27.99
Daily Change
-0.74 -2.58%
Monthly
-19.85%
Yearly
-4.08%
Q2 Forecast
27.21

Agios Pharmaceuticals reported $38.46M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Arrowhead Research USD 41.74M 4.28M Mar/2026
Astellas Pharma JPY 234.7B 12.92B Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Exelixis USD 139.6M 16.58M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026